Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on ...

An adverse event (or side effect) is any unwanted medical occurrence in a patient who has been given a medicinal product. This can be any unfavourable and unintended sign, symptom, or disease ...

Pozíciók keresése Mi a Novartis-nál büszkék vagyunk arra, amit csinálunk, hiszen a munkánk rendkívüli hatással lehet az emberek életére. Ez nem csak egy munkahely, itt tanulni, újítani, fejlődni lehet ...

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

Inclusion criteria For Cohort 1, Patient who meets all the following criteria can be included in this study: 1. Age ≥ 18 years at the time of signing the ICF; 2. Patient with a documented diagnosis of ...

Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC) ...

Treating advanced prostate cancer demands more than clinical progress—it demands a new era of care, fueled by relentless innovation, collaborative efforts, and an unwavering push toward personalized ...

主な役割責任早期化合物の安全性評価を行いチームへ適切に評価内容を伝える。承認申請資料を作成し，当局からの照会回答を含む承認申請全般に責任をもつ。治験届に関する資料作成を行い，当局からの照会対応を含む治験届業務全般に責任をもつ。当局に対する相談について非臨床安全性 ...